Bone Biologics Co. (NASDAQ:BBLG) Short Interest Down 31.3% in August

Bone Biologics Co. (NASDAQ:BBLG) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 12,500 shares, a decrease of 31.3% from the August 15th total of 18,200 shares. Approximately 2.4% of the shares of the stock are sold short. Based on an average trading volume of 2,060,000 shares, the days-to-cover ratio is presently 0.0 days.

Bone Biologics Price Performance

BBLG traded down $0.39 on Friday, reaching $0.80. The stock had a trading volume of 661,257 shares, compared to its average volume of 822,625. The firm has a 50-day moving average of $1.49 and a 200-day moving average of $1.68. Bone Biologics has a fifty-two week low of $0.80 and a fifty-two week high of $10.56.

Bone Biologics (NASDAQ:BBLG) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.39) by $0.72. Analysts anticipate that Bone Biologics will post -3.17 earnings per share for the current fiscal year.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.